MNPR
Monopar Therapeutics Inc
88.80$
-0.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.5% | +21.3% | -19.4% | -15.5% | +893.3% | -8.6% | -2.2% | +167.7% | -2.4% | -1.9% | -2.2% | |
| – | -14.4% | +21.5% | -19.4% | -15.5% | +893.3% | -8.6% | -2.4% | +168.1% | -2.5% | -1.9% | -2.2% | |
| – | +31.7% | +7.5% | -21.6% | -1.6% | +661.1% | -13.3% | -0.5% | +223.2% | -51.6% | -15.0% | +0.4% | |
| – | -14.5% | +21.0% | -19.0% | -15.4% | +900.2% | -9.4% | -2.4% | +169.8% | -2.3% | -2.1% | -2.3% | |
| – | -11.3% | -18.3% | -24.1% | +3.1% | +367.9% | -71.6% | +11.5% | +58.7% | +9.5% | -10.4% | +59.3% | |
| – | -11.3% | -18.3% | -24.1% | +3.1% | +367.9% | -71.6% | +6.1% | +62.2% | +6.5% | -10.1% | +63.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -11.3% | -18.3% | -24.1% | +3.1% | +100.8% | -33.8% | +6.1% | +60.2% | +7.8% | -10.1% | +63.4% | |
| – | -15.5% | +33.8% | -18.5% | -18.8% | +1,012.6% | -2.6% | -2.6% | +171.2% | -2.6% | -1.8% | -3.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.6% | +7.2% | +9.6% | -34.4% | +0.0% | -39.2% | +0.2% | +1.8% | -6.1% | +27.5% | +0.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.